| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H’27 |
| 10 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Whitehawk Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders on June 11, 2026 (the “Annual Meeting”). At the Annual Meeting, 40,375,023 shares of common stock of the Company, representing approximately 82% of the ... |
| 21 May 2026 |
8-K: Other Events
Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations |
| 13 May 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 12, 2026, by and among Whitehawk Therapeutics, Inc., a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A attached to this A... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
MORRISTOWN, NJ, November 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conj... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
MORRISTOWN, NJ, August 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatment... |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Whitehawk Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders on June 11, 2025 (the “Annual Meeting”). At the Annual Meeting, 28,690,008 shares of common stock of the Company, representing approximately 61% of the ... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
MORRISTOWN, NJ, May 8, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, ... |
| 26 Mar 2025 |
8-K: Completion of Acquisition or Disposition of Assets
On March 25, 2025, Whitehawk Therapeutics, Inc. (the “Company”) completed its previously announced sale of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. (the “Divestiture”) pursuant to the Stock Purchase Agreem... |
| 18 Mar 2025 |
8-K: Results of Operations and Financial Condition; Amendments to Articles/Bylaws; Change in Fiscal Year
(as amended and restated on August 26, 2021, December 6, 2022 and March 18, 2025) |
| 04 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Submission of Matters to a Vote of Security Holders +1 more
THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of March 4, 2025 by and among Aadi Bioscience, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), the sever... |
| 20 Dec 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This Stock Purchase Agreement (this “Agreement”) is dated as of December 19, 2024, among KAKEN INVESTMENTS INC., a Delaware corporation (“Purchaser”), KAKEN PHARMACEUTICAL CO., LTD. (“Guarantor”), Aadi Bioscience, Inc., a Delaware corpor... |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
FYARRO® sales of $7.2 million for Q3 2024, reflecting 21% year over year sales growth |
| 30 Sep 2024 |
8-K: Other Events
As previously reported, in June 2022, EOC Pharma (Hong Kong) Limited (“EOC”) filed a Request for Arbitration with the International Chamber of Commerce’s International Court of Arbitration against Aadi Bioscience, Inc. (the “Company”). I... |
| 19 Sep 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
We are happy to inform you that as a valued member of Aadi Bioscience, Inc. (“Aadi” or the “Company”), the Company has approved your eligibility to receive a bonus (the “Retention Bonus”) in the amount of $[___________] if you remain an ... |
| 22 Aug 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 16, 2024, Loretta Itri, M.D. notified the board of directors of the Company (the “Board”) that her employment as Chief Medical Officer will cease effective October 1, 2024. |
Loading...